President’s Donald Trump’s budget proposal should be treated as a genuine, credible threat to science, said Richard Klausner, a biotechnology entrepreneur who led NCI through the years of the doubling of the NIH budget.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
